A wide variety of structurally unrelated compounds are substrates of P-gp, and the penetration of many therapeutic agents into the CNS is significantly limited by P-gp, posing a significant challenge in the treatment of brain disorders such as brain tumours, epilepsy, and neurodegenerative diseases [9, 10]. The gene discussed is PGP; the disease is epilepsy.